- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03949855
Belimumabe com Rituximabe para Nefropatia Membranosa Primária (REBOOT)
Eficácia de belimumabe e rituximabe em comparação com rituximabe isoladamente para o tratamento de nefropatia membranosa primária (ITN080AI)
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy.
Background:
Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life.
Primary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys. This damage can cause the loss of too much protein in the urine.
Drugs used to treat MN aim to reduce the attack by one's own immune system on the kidneys by blocking inflammation and reducing the immune system's function. These drugs can have serious side effects and often do not cure the disease. There is a need for new treatments for MN that are better at improving the disease while reducing fewer treatment associated side effects.
In this study, researchers will evaluate if treatment with a combination of two different drugs, belimumab and rituximab, is effective at blocking the immune attacks on the kidney compared to rituximab alone. Rituximab works by decreasing a type of immune cell, called B cells. B cells are known to have a role in MN. Once these cells are removed, disease may become less active or even inactive. However, after stopping treatment, the body will make new B cells which may cause disease to become active again.
Belimumab works by decreasing the new B cells produced by the body and, may even change the type of new B cells subsequently produced. Belimumab is approved by the US Food and Drug Administration (FDA) to treat systemic lupus erythematosus (also referred to as lupus or SLE). Rituximab is approved by the FDA to treat some types of cancer, rheumatoid arthritis, and vasculitis. Neither rituximab nor belimumab is approved by the FDA to treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but has been tested in other autoimmune diseases, including lupus nephritis and Sjögren's syndrome.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This trial is a two-part study (Part A and Part B) of adults with primary membranous nephropathy (MN), ages 18-75 inclusive. The study will be conducted at multiple sites in the United States and Canada.
Part A: Open-label Phase
Part A is an open-label, PK study to compare belimumab exposure between participants who have "low" proteinuria (≥ 4 to < 8 g/day) and "high" proteinuria (≥ 8 g/day) at Visit -1.
Initially Part A planned to enroll 20 individuals with primary MN: 10 individuals with low proteinuria and 10 individuals with high proteinuria. All Part A participants received 200 mg subcutaneous belimumab weekly, the initially approved dose of belimumab in SLE, for 52 doses (weeks 0-51). Trough serum belimumab levels would be obtained weekly following the first 4 doses of belimumab. All participants would receive rituximab 1000 mg IV at weeks 4 and 6, and are followed after the 52 week treatment period on no study medication until week 156.
Belimumab trough levels were to be analyzed after all 20 participants received the first 4 doses to compare the belimumab exposure between the low and high proteinuria groups. If the belimumab exposure was not comparable between the high and low proteinuria groups, the belimumab dose would be doubled to 400 mg/weekly for participants with high proteinuria in Part B. Dose determination for participants with high proteinuria in Part B would be made by an adjudication committee comprised of the Protocol Chair, NIAID Medical Monitor, ITN Clinical Trial Physician, and Rho Scientist, in consultation with the belimumab PK expert at GSK.
Due in part to the observed imbalance in enrollment between the high and low proteinuria groups, an ad hoc PK analysis was conducted. The serum belimumab trough levels of the first 12 participants (8 with high proteinuria and 4 with low proteinuria) who received the first 4 belimumab doses were analyzed to compare belimumab exposure between the low and high proteinuria groups.
The results of the PK analysis were reviewed by the adjudication committee, who determined that the results did not support doubling the dose of belimumab in individuals with high proteinuria nor did it identify a new proteinuria threshold that warranted an increased belimumab dose. The belimumab PK expert at GSK concurred. Thus, enrollment into Part A has been suspended, and all participants in Part B are to receive the same dose of belimumab. All participants currently enrolled in Part A continue to receive belimumab and rituximab as previously planned and are undergoing the safety assessments as presented in Appendix A.
All enrolled participants in Part A will be followed until week 156 and will be assessed for the same study endpoints as participants in Part B.
Part B: Randomized Phase
Part B is a prospective, randomized, phase II, double-blind, placebo-controlled, multicenter clinical trial in adults with primary MN to assess the effectiveness of belimumab and rituximab at treating primary MN. Part B is commencing after the completion of the ad hoc PK analysis, which did not support increasing the belimumab dose in participants with high proteinuria.
A total of 58 participants will be randomized into two treatment arms.
Randomization will be stratified by low (≥ 4 to < 8 g/day) and high proteinuria (≥ 8 g/day). Eleven participants who entered Part B prior to protocol version 7.0 were randomized at a 1:1 ratio; 47 participants entering at or after protocol version 7.0 will be randomized at a 3:1 ratio. A total of 41 participants are projected to be enrolled in the belimumab and rituximab arm and 17 participants in the belimumab placebo and rituximab arm. The effectiveness of belimumab with rituximab will be evaluated using a hybrid control arm that combines participants who receive belimumab placebo and rituximab in this study and the subgroup of subjects with primary MN in the MENTOR trial who were anti-PLA2R positive at baseline and received rituximab alone. The randomized arms will also be used to evaluate the safety of adding belimumab to rituximab in primary MN and to support mechanistic studies.
Participants randomized to the belimumab and rituximab arm will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. This dosing regimen is based on the recommended dosing of subcutaneous belimumab for lupus nephritis. Participants randomized to the belimumab placebo and rituximab arm will receive subcutaneous belimumab placebo according to the same dose and schedule.
Participants in both arms will receive rituximab 1000 mg IV at weeks 4 and 6.
At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and, defined as fulfilling at least two of the following three criteria at week 30, will receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):
- Anti-PLA2R levels is ≥ 25% of baseline
- Proteinuria is ≥ 50% of baseline
- Serum albumin is < 2.8 g/dL
After the 52 week treatment period, all participants will be followed on no study medication with assessment of the primary endpoint (CR or PR) at week 104.
The primary endpoint will be assessed at week 104 because the proteinuric response to treatment is known to lag behind the active treatment period and is recommended to be assessed at least 18 months after the initiation of therapy. There will be a tolerance endpoint at week 156 to determine if treatment with belimumab with rituximab results in a more durable remission compared to rituximab alone, and to assess the rate of relapse after having achieved complete or partial remission.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Recrutamento
- University of Alabama at Birmingham School of Medicine: Division of Nephrology
-
Investigador principal:
- Dana Rizk
-
Contato:
- Maria El Hachem
- Número de telefone: 205-975-0549
- E-mail: mehachem@uabmc.edu
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Recrutamento
- University of Arkansas
-
Contato:
- Gail Runnells
- Número de telefone: 501-526-7956
- E-mail: RunnellsGailAnn@uams.edu
-
Investigador principal:
- Srilakshmi Ravula
-
-
California
-
San Francisco, California, Estados Unidos, 94146
- Recrutamento
- University of California San Francisco
-
Contato:
- Juan Espinoza
- Número de telefone: 415-502-3618
- E-mail: Juan.Espinoza@ucsf.edu
-
Investigador principal:
- Raymond Hsu
-
Stanford, California, Estados Unidos, 94305
- Recrutamento
- Stanford University School of Medicine: Division of Nephrology
-
Investigador principal:
- Fahmeedah Kamal
-
Contato:
- Elizabeth Chen
- E-mail: echen15@stanford.edu
-
Contato:
- Brittany Yeung
- Número de telefone: (650) 498-3116
- E-mail: yeungb@stanford.edu
-
Torrance, California, Estados Unidos, 90502
- Recrutamento
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:Division of Nephrology and Hypertension
-
Contato:
- Janine LaPage
- Número de telefone: 310-222-4104
- E-mail: jlapage@lundquist.org
-
Investigador principal:
- Sharon G. Adler
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- University of Colorado
-
Investigador principal:
- Amber Podoll, MD
-
Contato:
- Lizzy Kickery
- Número de telefone: 303-724-7790
- E-mail: Lizzy.kickery@cuanschutz.edu
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Recrutamento
- Mayo Clinic Jacksonville: Department of Nephrology and Hypertension
-
Investigador principal:
- Nabeel Aslam
-
Contato:
- Tia Wilkes
- Número de telefone: 904-953-3636
- E-mail: wilkes.quantia@mayo.edu
-
Miami, Florida, Estados Unidos, 33136
- Recrutamento
- University of Miami Miller School of Medicine, Div of Nephrology
-
Investigador principal:
- Jair Munoz Mendoza
-
Contato:
- Carlos D Bidot
- Número de telefone: 305-243-8793
- E-mail: cbidot2@med.miami.edu
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Recrutamento
- Johns Hopkins
-
Investigador principal:
- Duvuru Geetha
-
Contato:
- Kristin Lyman
- Número de telefone: (734) 276-1248
- E-mail: klyman1@jh.edu
-
Bethesda, Maryland, Estados Unidos, 20892
- Recrutamento
- National Institutes of Health Clinical Center
-
Contato:
- Lilian V. Howard, CRNP
- Número de telefone: 301-594-0298
- E-mail: howardlv@mail.nih.gov
-
Investigador principal:
- Meryl A. Waldman
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48104
- Recrutamento
- University of Michigan
-
Investigador principal:
- Andrea Oliverio
-
Contato:
- Marie Grutt
- Número de telefone: 734-232-9358
- E-mail: mfrb@med.umich.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Recrutamento
- University of Minnesota Health Clinical Research Unit
-
Contato:
- Brady Wallner
- Número de telefone: 612-626-3415
- E-mail: walln080@umn.edu
-
Investigador principal:
- Patrick H. Nachman
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- Washington University in St. Louis
-
Investigador principal:
- Tinting Li
-
Contato:
- Emily Green
- Número de telefone: 314-273-0339
- E-mail: green.e@wustl.edu
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- Recrutamento
- University of Nebraska
-
Investigador principal:
- Prasanth Ravipati
-
Contato:
- Tammy Jones, RN
- Número de telefone: 402-559-4335
- E-mail: tamjones@unmc.edu
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Recrutamento
- Columbia University Medical Center: Division of Nephrology
-
Contato:
- Anup Pradhan
- Número de telefone: 212-305-5037
- E-mail: arp2209@cumc.columbia.edu
-
Investigador principal:
- Andrew S. Bomback
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599-
- Recrutamento
- University of North Carolina School of Medicine: Division of Nephrology and Hypertension, Kidney Center
-
Contato:
- Anne Froment
- Número de telefone: 919-445-2622
- E-mail: anne_froment@med.unc.edu
-
Investigador principal:
- Vimal K. Derebail
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Recrutamento
- Cleveland Clinic
-
Investigador principal:
- John Sedor
-
Contato:
- Sandra Hodnick
- Número de telefone: 216-444-0124
- E-mail: hodnics@ccf.org
-
Columbus, Ohio, Estados Unidos, 43210
- Recrutamento
- Ohio State University Wexner Medical Center: Division of Nephrology
-
Contato:
- Laci Roberts
- Número de telefone: 614-685-5323
- E-mail: laci.roberts@osumc.edu
-
Investigador principal:
- Isabelle Ayoub
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- University of Pennsylvania: Department of Medicine: Renal-Electrolyte and Hypertension Division
-
Contato:
- Krishna Kallem, MD, MPH
- Número de telefone: 484-358-0315
- E-mail: Krishna.Kallem@pennmedicine.upenn.edu
-
Investigador principal:
- Gaia Coppock
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99204
- Recrutamento
- Providence Medical Research Center, Providence Health Care: Nephrology
-
Contato:
- Nicole Maser, MSH, RN
- Número de telefone: 509-474-5315
- E-mail: nicole.maser@providence.org
-
Investigador principal:
- Katherine R. Tuttle
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Subjects must meet all of the following criteria to be eligible for this study-
-
Age 18 to 75 years inclusive
-
Diagnosis of one of the following:
- Primary MN confirmed by a kidney biopsy within the past 5 years
- Primary MN that is relapsing following a CR (Section 3.3.1) or PR (Section 3.3.2), confirmed by a kidney biopsy within the past 7 years
- Nephrotic syndrome with eGFR > 60 mL/min/1.73m2 and no history of immunosuppressant treatment (e.g. glucocorticoids, cyclophosphamide, cyclosporine A, tacrolimus, B-cell depleting agent) for nephrotic syndrome, and without evidence of a secondary cause of nephrotic syndrome
- Nephrotic syndrome and a contraindication to kidney biopsy (e.g., anticoagulation, solitary kidney, body habitus that increases the risk of biopsy, or other contraindication in the opinion of the investigator), and without evidence of a secondary cause of nephrotic syndrome
-
Serum anti-PLA2R positive
-
eGFR ≥ 30 mL/min/1.73m2 while on maximally tolerated RAS blockade
-
Proteinuria:
- ≥ 4 and < 8 g/day that has persisted for at least the previous 3 months while on maximally tolerated RAS blockade. Documentation of persistent proteinuria may be from a 24-hour collection or calculated from a spot urine collection. Or,
- ≥ 8 g/day while on maximally tolerated RAS blockade
-
Blood pressure while on maximally tolerated RAS blockade:
- Systolic blood pressure ≤ 140 mmHg
- Diastolic blood pressure ≤ 90 mmHg
Exclusion Criteria:
Subjects meeting any of the following criteria will not be eligible for this study-
-
Secondary cause of MN (e.g., SLE, drug, infection, malignancy) suggested by review of the patient's medical history and/or clinical presentation
-
Rituximab use within the previous 12 months
-
Rituximab use > 12 months ago:
- With an undetectable CD19 B cell count, or
- Did not result in a CR (Section 3.3.1) or PR (Section 3.3.2) with rituximab treatment alone (e.g., without other immunosuppressive or immunomodulatory therapy)
-
Use of anti-B cell therapy other than rituximab within the previous 12 months (or 5 half-lives, whichever is greater)
-
Cyclophosphamide use within the past 3 months
-
Use of other immunosuppressive medications such as cyclosporine or tacrolimus within the past 30 days
-
Use of systemic corticosteroids within the past 30 days
-
Use of any biologic investigational agent (defined as any drug not approved for sale in the country it is used) in the previous 12 months
-
Use of any non-biologic investigational agent in the past 30 days (or 5 half-lives, whichever is greater)
-
Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥ 9.0%
-
Patients with diabetic glomerulopathy on renal biopsy that is:
- Greater than Class I diabetic glomerulopathy, or
- Class I diabetic glomerulopathy with a history of poor diabetic control (e.g., HbA1c ≥ 9.0%) since time of biopsy
-
Unstable kidney function defined as > 20% decrease in eGFR during the previous 3 months due to primary MN, as determined by the site investigator in consultation with the protocol chair
-
Decrease in proteinuria by 50% or more during the previous 12 months
-
WBC count < 3.0 x 103/μl
-
Absolute neutrophil count < 1.5 x 103/μl
-
Moderately severe anemia (hemoglobin < 9 g/dL)
-
History of primary immunodeficiency
-
Serum IgA < 10 mg/dL
-
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2x the upper limit of normal (ULN)
-
Positive HIV serology
-
Positive HCV serology, unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 24 weeks after cessation of therapy)
-
Evidence of current or prior infection with hepatitis B, as indicated by positive HBsAg or positive HBcAb
-
Positive QuantiFERON - TB Gold test results. PPD tuberculin test may be substituted for QuantiFERON - TB Gold test
-
History of lung disease with FVC < 70% predicted, DLCO < 70% predicted, or requiring supplemental oxygen
-
History of malignant neoplasm within the last 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years
-
Absence of individualized, age-appropriate cancer screening
-
Women of child-bearing potential who are pregnant, nursing, or unwilling to be sexually inactive or use FDA-approved contraception until week 104
-
Acute or chronic infection, including current use of suppressive therapy for chronic infection, hospitalization for treatment of infection in the past 60 days, or parenteral anti-microbial (including anti-bacterial, anti-viral, or anti-fungal agents) use in the past 60 days for infection
-
History of an anaphylactic reaction or known sensitivity or intolerance to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies, including rituximab or belimumab
-
Evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk
-
Evidence of current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence in the past 12 months
-
Vaccination with a live vaccine within the past 30 days
-
Other diseases or conditions or other clinically significant abnormal laboratory value which in the opinion of the investigator would put the patient at risk or confound the results of the study
-
Inability to comply with study and follow-up procedures
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part A: Low Proteinuria Group - Belimumab and Rituximab
Open-label pharmacokinetics (PK) phase. Participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6. Low proteinuria classification: The excretion of ≥4 to <8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day). |
Belimumab is a recombinant, human, IgG1λ monoclonal antibody. Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use. Standard Weekly dose: Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.
Outros nomes:
Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid. Dose: 1000 mg intravenously (IV), Week 4 and -6.
Outros nomes:
|
|
Experimental: Part A :High Proteinuria Group - Belimumab and Rituximab
Open-label pharmacokinetics (PK) phase. Participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6. High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day). |
Belimumab is a recombinant, human, IgG1λ monoclonal antibody. Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use. Standard Weekly dose: Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.
Outros nomes:
Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid. Dose: 1000 mg intravenously (IV), Week 4 and -6.
Outros nomes:
|
|
Experimental: Part B: Belimumab and Rituximab
Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6. At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):
|
Belimumab is a recombinant, human, IgG1λ monoclonal antibody. Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use. Standard Weekly dose: Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.
Outros nomes:
Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid. Dose: 1000 mg intravenously (IV), Week 4 and -6.
Outros nomes:
|
|
Comparador de Placebo: Part B: Placebo and Rituximab
Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab placebo 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6. At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):
|
Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid. Dose: 1000 mg intravenously (IV), Week 4 and -6.
Outros nomes:
The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use. Standard weekly dose: Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Participants in Complete or Partial Remission (CR or PR) at Week 104.
Prazo: Week 104
|
. CR is defined as proteinuria of ≤ 0.3 g/day with a serum albumin ≥ 3.5 g/dL. PR is defined as a 50% or greater decrease in proteinuria compared to baseline and proteinuria < 3.5 g/day glomerular filtration rate (eGFR) from baseline. |
Week 104
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proporção de participantes que atendem aos critérios para um segundo curso de rituximabe na semana 30
Prazo: Semana 30
|
Semana 30
|
|
|
Proporção de participantes em remissão completa ou parcial (CR ou PR) na semana 52 e na semana 156.
Prazo: Semana 52, Semana 156
|
Semana 52, Semana 156
|
|
|
Proporção de participantes em remissão completa (CR) na semana 52, semana 104 e semana 156.
Prazo: Semana 52, Semana 104, Semana 156
|
Semana 52, Semana 104, Semana 156
|
|
|
Proporção de participantes em PR, mas não em CR na Semana 52, Semana 104, Semana 156.
Prazo: Semana 52, Semana 104, Semana 156
|
Semana 52, Semana 104, Semana 156
|
|
|
É hora de recaída para participantes que alcançaram CR ou PR.
Prazo: Até 156 semanas (3 anos)
|
Até 156 semanas (3 anos)
|
|
|
Nível de proteinúria na semana 52, semana 104 e semana 156.
Prazo: Semana 52, Semana 104, Semana 156
|
Semana 52, Semana 104, Semana 156
|
|
|
Proporção de participantes em CR ou PR e anti-PLA2R negativo nas semanas 52, 104 e 156
Prazo: Semana 52, Semana 104, Semana 156
|
Semana 52, Semana 104, Semana 156
|
|
|
Proporção de participantes em PR e anti-PLA2R negativo nas semanas 52, 104 e 156
Prazo: Semana 52, Semana 104, Semana 156
|
Semana 52, Semana 104, Semana 156
|
|
|
Proporção de participantes em PR, mas não em CR, e que são anti-PLA2R negativos nas semanas 52, 104 e 156
Prazo: Semana 52, Semana 104, Semana 156
|
Semana 52, Semana 104, Semana 156
|
|
|
Proporção de participantes que são negativos para anti-PLA2R nas semanas 52, 104 e 156
Prazo: Semana 52, Semana 104, Semana 156
|
Semana 52, Semana 104, Semana 156
|
|
|
Qualidade de vida nas semanas 52, 104 e 156
Prazo: Semana 52, Semana 104, Semana 156
|
Semana 52, Semana 104, Semana 156
|
|
|
Incidência de Eventos Adversos (EAs).
Prazo: Semana 0 a Semana 52
|
Semana 0 a Semana 52
|
|
|
Incidence of Grade 3 or Higher Infectious Adverse Events (AEs): By Treatment Group
Prazo: Week 0 to Week 52
|
Reference: NCI-CTCAE manual titled, National Cancer Institute (NCI)s Common Terminology Criteria for Adverse Events Version 5.0 (published November 27, 2017). |
Week 0 to Week 52
|
|
Incidence of Arterial Thromboembolic Events: By Treatment Group
Prazo: Week 0 to Week 52
|
Peripheral vascular embolism, mesenteric infarct, or myocardial infarction. |
Week 0 to Week 52
|
|
Incidence of Venous Thromboembolic Events: By Treatment Group
Prazo: Week 0 to Week 52
|
Venous thromboembolic event (VTE) is defined as a symptomatic deep vein thrombosis (DVT): the formation of a blood clot in a deep vein, detected by systematic compression ultrasonography, symptomatic DVT, or symptomatic fatal or non-fatal pulmonary embolism (PE). An embolism is a clot in the blood that forms and blocks a blood vessel. A pulmonary embolism is a blood clot that has travelled from elsewhere in the body through the blood stream to block the main artery of the lung or one of its branches. |
Week 0 to Week 52
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Cadeira de estudo: Patrick Nachman, University of Minnesota, Department of Medicine, Division of Renal Diseases and Hypertension
- Cadeira de estudo: Iñaki Sanz, Emory University, Department of Medicine, Division of Rheumatology
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças autoimunes
- Doenças do sistema imunológico
- Glomerulonefrite
- Nefrite
- Nefrose
- Síndrome nefrótica
- Glomerulonefrite Membranosa
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Anticorpos, monoclonais, derivados de murinos
- Rituximabe
- belimumab
Outros números de identificação do estudo
- DAIT ITN080AI
- NIAID CRMS ID#:38478 (Outro identificador: DAIT NIAID)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
Prazo de Compartilhamento de IPD
On average, within 24 months after database lock for the trial.
Critérios de acesso de compartilhamento IPD
Open access.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .